Advertisement

Correlation Between Superoxide Dismutase Serum Level Alteration with Neck Metastatic Tumor Post Cisplatin–Paclitaxel Chemotherapy Response in Nasopharyngeal Carcinoma Patients

  • Achmad Chusnu RhomdhoniEmail author
  • Puji Kurniawan
  • Titiek Hidayati
Original Article
  • 56 Downloads

Abstract

Nasopharyngeal carcinoma (NPC) is a malignant tumor in the nasopharynx. The patients treated with neoadjuvan combination chemotherapy cisplatin–paclitaxel while waiting a radiotherapy. This combination can produce a very high reactive oxygen species (ROS) level. Our body has a protective mechanism against oxidant through superoxide dismutase (SOD) that can inhibit DNA chain damage from ROS induction produced by chemotherapy in NPC patients. This study aimed to analyze the correlation between SOD level alteration with neck metastatic tumor response after cisplatin–paclitaxel chemotherapy. This was a cohort study. Thirty samples examined for neck metastasis tumor volume (VTM) and serum SOD were examined with ELISA pre- and postchemotherapy. Statistical significance was defined as p < 0.05. Mean SOD serum level pre-chemotherapy and post-chemotherapy were was 179.5 and 209.1, respectively. Mean tumor metastaic volume pre and post chemotherapy were 127.3 and 62.7, respectively. The correlation test with the result (r) 0.180 and p = 0.340. There was no correlation between SOD serum level alteration with VTM volume post cisplatin–paclitaxel chemotherapy in NPC patients.

Keywords

Superoxide dismutase Metastasic tumor Cisplatin–paclitaxel chemotherapy Nasopharyngeal carcinoma 

References

  1. 1.
    Rofi’i A, Fatchiyah F, Rahayu P, Muhyi R, Sumitro SB (2013) Reactive oxygen species, NF-kB, and p53 level in tissue of undifferentiated nasopharyngeal carcinoma. Oxid Antioxid Med Sci 2:1–5CrossRefGoogle Scholar
  2. 2.
    Brennan B (2006) Nasopharyngeal carcinoma. Orphanet J Rare Dis 1:23CrossRefGoogle Scholar
  3. 3.
    Agarwala SS (1999) Adjuvant chemotherapy in head and neck cancer. Hematol Oncol Clin N Am 13(4):743–752CrossRefGoogle Scholar
  4. 4.
    Limberaki E, Eleftheriou P, Gasparis G et al (2011) Cortisol level and serum antioksidan status following chemotherapy. Health 3:512–517CrossRefGoogle Scholar
  5. 5.
    Salzman RKR, Pacal L, Kankova K, Tomndl J, Horakova Z et al (2006) Increased level of malondialdehyde as negative prognostic factor for recurrent head and neck squamous cell carcinoma. Otorinolaryngol Foniatr 11:925–932Google Scholar
  6. 6.
    Rubin SC (2004) Chemotherapy of gynecologic cancer. In: Lippincott Williams and Wilkins (ed) Society of gynecologic oncologists, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 101–126Google Scholar
  7. 7.
    Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2(11):2490–2518CrossRefGoogle Scholar
  8. 8.
    Lu H, Peng L, Yuan X, Hao Y, Lu Z, Chen J et al (2009) Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia. Cancer Treat Rev 35(4):345–353CrossRefGoogle Scholar
  9. 9.
    Malathi M, Vijaya M, Shivashankara AR (2011) The role of oxidative stress and the effect of radiotherapy on the plasma oxidant-antioxidan status in head and neck cancer. J Clin Res 5(2):249–251Google Scholar
  10. 10.
    Kaya E, Keskin L, Aydogdu I, Kuku I, Bayraktar N, Erkut MA (2005) Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin’s lymphoma. J Int Med Res 33(6):687–692CrossRefGoogle Scholar
  11. 11.
    Yariktas M, Doner F, Dogru H, Aynali G, Yonden Z, Delibas N (2003) Malondialdehyde levels and antioxidant enzyme activities in head and neck malign tumors. Süleyman Demirel Univ Sch Med J 10:65–67 (in Turkish) Google Scholar
  12. 12.
    Li YZ, Cai PQ, Xie CM, Huang ZL, Zhang GY, Wu YP et al (2013) Nasopharyngeal cancer: impact of skull base invasion on patients prognosis and its potential implications on TNM staging. Eur J Radiol 82(3):e107–e111CrossRefGoogle Scholar
  13. 13.
    Brockstein BE, Vokes EE (2006) Principles of chemotherapy in the management of head and neck cancer. In: Bailey BJ (ed) Head and neck surgery otolaryngology, 4th edn. Mosby, St Louis, pp 1427–1440Google Scholar
  14. 14.
    Eshragi AA, Bublik M, Water TR (2006) Mechanisms of chemotherapeutic-induced hearing loss and otoprotection. Drug Discov Today Dis Mech 3:125–130CrossRefGoogle Scholar
  15. 15.
    Fischel-Ghodsian N, Kopke RD, Ge X (2004) Mitochondrial dysfunction in hearing loss. Mitochondrion 4(5–6):675–694CrossRefGoogle Scholar

Copyright information

© Association of Otolaryngologists of India 2018

Authors and Affiliations

  • Achmad Chusnu Rhomdhoni
    • 1
    Email author
  • Puji Kurniawan
    • 1
  • Titiek Hidayati
    • 1
  1. 1.Department of Otolaryngology, Faculty of MedicineUniversitas Airlangga - Dr. Soetomo HospitalSurabayaIndonesia

Personalised recommendations